Lincoln Pharmaceuticals Ltd - 531633 - Corporate Action-Board to consider Dividend
we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, May 25, 2021, have Recommended a dividend of Rs. 1.50/- (i.e. 15% per share) per equity share of face value of Rs. 10.00/- for the year ended March 31, 2021, for approval of the members at the ensuring Annual General Meeting (AGM) of the Company. Lincoln Pharmaceuticals Ltd - 531633 - Board recommends Dividend
Lincoln Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 25, 2021, inter alia, has recommended a dividend of Rs. 1.50/- (i.e. 15% per share) per equity share of face value of Rs. 10.00/- for the year ended March 31, 2021, for approval of the members at the ensuring Annual General Meeting (AGM) of the Company. Lincoln Pharmaceuticals Ltd - 531633 - Outcome Of The Board Meeting
we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, May 25, 2021, have considered / approved / recommended, inter alia, the followings: (1) audited financial results (standalone and consolidated) for the quarter and year ended on March 31, 2021 along with the reports of auditors thereon. Recommended a dividend qf ~ 1.50/- (i.e. 15% per share) per equity share of face value of ~ 10.00/- for the year ended March 31, 2021, for approval of the members at the ensuring Annual General Meeting (AGM) of the Company. We also enclose herewith financial highlights of the Company for the aforesaid quarter. LINCOLN PHARMACEUTICALS LTD. - 531633 - Audited Financial Result For The Quarter And Year Ended March 31, 2021
we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, May 25, 2021, have considered / approved / recommended, inter alia, the followings: (1) audited financial results (standalone and consolidated) for the quarter and year ended on March 31, 2021 along with the reports of auditors thereon. Recommended a dividend qf ~ 1.50/- (i.e. 15% per share) per equity share of face value of ~ 10.00/- for the year ended March 31, 2021, for approval of the members at the ensuring Annual General Meeting (AGM) of the Company. We also enclose herewith financial highlights of the Company for the aforesaid quarter. Lincoln Pharmaceuticals Ltd - 531633 - Board to consider FY21 results & Dividend on May 25, 2021
Lincoln Pharmaceuticals Ltd has informed BSE that the Meeting of the Board of Directors of the Company is scheduled to be held on May 25, 2021, inter alia, to consider and approve the audited standalone and consolidated financial results of the Company for the quarter and year ended on March 31, 2021 and recommendation of dividend on equity shares of the Company, if any, along with any other business, if any.Further, in continuation to the Company's disclosure on closure of trading window dated March 31, 2021, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from April 01,*2021 and shall reopen after the expiry of 48 hours from the time the result becomes generally avallable. Lincoln Pharmaceuticals Ltd - 531633 - Update on board meeting
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve Update on board meeting LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Intimation for Consider And Approve The Audited Standalone And Consolidated Financial Results Of The Company.
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve the audited standalone and consolidated financial results of the Company for the quarter and year ended on March 31, 2021 and recommendation of dividend on equity shares of the Company, if any, along with any other business, if any. Further, in continuation to our disclosure on closure of trading window dated March 31, 2021, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from April 01, 2021 and shall reopen after the expiry of 48 hours from the time the result becomes generally available. LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement Under Regulation 30 (LODR) - Clarification On Increase In Volume
we would like to clarify that company has made timely disclosures of all the events and information which fall under the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and which otherwise would be necessary for investors to know for making sound investment decision. we hereby confirm that there are no other major events which have occurred or likely to occur in near future which, can have major bearing on the operations / performance of the Company or Company's working or financial positions including all price sensitive information of the scrip. If any of such event will occur then the Company will immediately intimate the same to the exchanges in due compliance of relevant regulations. Lincoln Pharmaceuticals Ltd - 531633 - Clarification sought from Lincoln Pharmaceuticals Ltd
The Exchange has sought clarification from Lincoln Pharmaceuticals Ltd on April 30, 2021, with reference to Movement in Volume.The reply is awaited. LINCOLN PHARMACEUTICALS LTD. - 531633 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayLINCOLN PHARMACEUTICALS LTD. 2CINL24230GJ1995PLC024288 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.50 4Highest Credit Rating during the previous FY A 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: NIREN DESAI Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: nirendesai@lincolnpharma.com Name of the Chief Financial Officer: DARSHIT SHAH Designation: CHIEF FINANCIAL OFFICER EmailId: darshit@lincolnpharma.com Date: 23/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.